https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Promo Image

Viread-Videx EC Drug Interactions -- What's a Person to Do?

A few months ago, Bristol-Myers Squibb released data from a study of the interaction of Viread (tenofovir) with Videx EC (enteric-coated ddI). The results were also recently presented at the XIV International AIDS Conference. Viread needs to be tak...

Promo Image
Lipodystrophy/Body Fat

Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study

Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (Abstract 28) Presented by David Nolan

Two important studies were presented back to back. David No...

Promo Image

New Safety Information for Videx (Didanosine, ddI) Used With Ribavirin

The VIDEX (Didanosine, ddI) label has been revised to include new, precautionary information about co-administration of VIDEX and ribavirin (RBV) in HIV/HCV co-infected patients. Literature reports1, 2 and 24 cases submitted to the FDA Adverse Event ...

Promo Image

The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor Hypersusceptibility: A Prospective Cohort Analysis

The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Hypersusceptibility: A Prospective Cohort Analysis (ThOrB1388) Authored by R. Haubrich, N. Hellmann, P. Keiser, C. Kemper, D. Forthal, J. Leedom, M. Leibowitz, D. ...

Promo Image

Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions

Tenofovir DF (TDF) and Didanosine EC (ddI EC): Investigation of Pharmacokinetic (PK) Drug-Drug and Drug-Food Interactions (LbPeB9026) Authored by A.K. Cheng, B.P. Kearney, B. Damle, A. Plummer, J. Sayre, X. Zhang, K. RyanView the original abstr...

Promo Image

Efficacy and Safety of Amprenavir/Ritonavir 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011

Efficacy and Safety of Amprenavir (APV)/Ritonavir (RTV) 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (TuPeB4463) Authored by J. Nadler, J. Gathe, R. Pollard, G. Richmond, Q. Liao, T. Lancaster, S. ...

Promo Image

Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results

Abacavir/Lamivudine (ABC/3TC) in Combination With Efavirenz (NNRTI), Amprenavir/Ritonavir (PI) or Stavudine (NRTI): ESS40001 (CLASS) Preliminary 48-Week Results (TuOrB1189) Authored by J.A. Bartlett, J. Johnson, G. Herrera, N. Sosa, A.E. Rodrig...

Promo Image

Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens

Researchers assessed the adverse events (AEs) and impact of an efavirenz-containing regimen versus a protease inhibitor-containing regimen on quality of life (QOL), emotional status (ES), and adherence of HIV-1-infected patients in a prospective, ran...

Promo Image
Hepatitis C

A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV

Protease inhibitors (PIs), a class of HIV medications, can greatly reduce the number of new, infectious copies of HIV made inside cells. If PIs succeed in slowing down the production of HIV, HIV infection would not spread inside the body as quickly a...

Promo Image
News

FDA Approves New Dosing for Amprenavir and Ritonavir Combination

The FDA sent the following email on February 6, 2002:

On February 5, 2002, FDA approved a new dosing regimen for Agenerase (amprenavir) and Norvir (ritonavir) used in combination. The "Dosage and Administration" section of the amprenavir package ins...